Sanitary Registration of Heberprot-P®, an innovative biotechnological medicine for the treatment of diabetic foot ulcers

Authors

Keywords:

Heberprot-P®, Sanitary Registration, innovative biotechnology, National Regulatory Authority of Mexico, Cofepris

Abstract

Introduction: Heberprot-P® obtained its first Sanitary Registration in Cuba in 2006, and it is currently approved in 26 other countries.

Objective: Describe the sanitary registration process in Mexico of the biotechnological drug Heberprot-P® for the treatment of diabetic foot ulcers.

Methods: The sanitary registration process of Heberprot-P® followed the guidelines of the sanitary regulations of Mexico on the basis of the General Health Law and the Regulation of Supplies for Health. The Pharmacopoeia of the United Mexican States and the official Mexican standards were also revised in order to comply with the requirements for the marketing of medicines in this territory.

Results: The registration process began in June 2017 in Mexico with actions to complete the documents and information required in the sanitary registration file to be submitted. Among them are the considerations of the Sub-committee on the Evaluation of Biotechnological Products and the Committee on New Molecules, the evaluation of the file by an Authorized Third Party and documents issued by the National Center for Pharmacovigilance and the Mexican Institute of Industrial Property. The application for sanitary registration was submitted to Cofepris and this was approved in May 2018.

Conclusions: The work with groups of experts allowed the Mexican authority to do a more expeditious work based on the evidence of the evaluations carried out that are part of the information of the sanitary registry. As a result of this process, Heberprot-P® was granted the Sanitary Registry in May 2018 and COFEPRIS recognized it as an innovative biotechnological medicine.

Downloads

Download data is not yet available.

Published

2021-11-29

How to Cite

1.
Rodríguez Silva A, Quiñones Maya Y, López-Mola E, Palmero Molina M, Costa Anguiano L, Castro Velazco J, et al. Sanitary Registration of Heberprot-P®, an innovative biotechnological medicine for the treatment of diabetic foot ulcers. Rev Cubana Salud Pública [Internet]. 2021 Nov. 29 [cited 2025 Feb. 12];47(4). Available from: https://revsaludpublica.sld.cu/index.php/spu/article/view/3126